Karus Therapeutics
is a pharmaceutical research company that develops drugs to treat cancer and heart diseases... Read moreKarus Therapeutics
is a pharmaceutical research company that develops drugs to treat cancer and heart diseases... Read more
CEO
Add
News
Dec 03, 2019
BioPortfolio
Karus Therapeutics: Karus Therapeutics to Announce Positive New Data from Phase I RelapsedRefractory BCell Lymphoma Trial at ASH.
Nov 30, 2018
BioPortfolio
Karus Therapeutics: Karus Therapeutics Ltd Pharmaceuticals Healthcare Deals and Alliances Profile Report Updated 13112018 Prices from USD $250
Oct 06, 2018
BioPortfolio
Karus Therapeutics: Karus Therapeutics Ltd Pharmaceuticals Healthcare Deals and Alliances Profile Report Updated 24072018 Prices from USD $250
Aug 15, 2018
BioPortfolio
Karus Therapeutics: Karus Therapeutics Ltd Pharmaceuticals Healthcare Deals and Alliances Profile Report Updated 23042018 Prices from USD $250
Apr 18, 2018
Karus Therapeutics Blog
Karus Therapeutics Blog AACR Annual Meeting 2018, Chicago, USA
Apr 06, 2018
BioPortfolio
Karus Therapeutics: Karus Therapeutics Ltd Pharmaceuticals Healthcare Deals and Alliances Profile Report Updated 12032018 Prices from USD $250
Nov 20, 2017
Karus Therapeutics Blog
Karus Therapeutics Blog Functional characterization of a novel somatic mutation of PIK3CB
Sep 28, 2017
Karus Therapeutics Blog
Karus Therapeutics Blog CHI DoT 11th Annual Next-Generation Histone Deacetylase Inhibitors conference, Boston
Sep 27, 2017
Karus Therapeutics Blog
Karus Therapeutics Blog CHI DoT 10th Annual Kinase Inhibitor Discovery conference, Boston
Sep 18, 2017
4-traders
Karus Therapeutics: IP : Karus Therapeutics Ltd - Announces first cancer patients dosed with KA2507, a small molecule HDAC6-selective inhibitor, in a Phase I clinical trial
Karus Therapeutics Competitors
1
2
3
4
5
6
7
8
9
10